153 related articles for article (PubMed ID: 9236571)
1. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
[TBL] [Abstract][Full Text] [Related]
2. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
Talwalker S
J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
4. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
5. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study.
Saumier D; Duong A; Haine D; Garceau D; Sampalis J
J Nutr Health Aging; 2009 Nov; 13(9):808-12. PubMed ID: 19812871
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E genotype and gender influence response to tacrine therapy.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
9. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
10. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
11. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
12. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
Grossberg GT; Schmitt FA; Meng X; Tekin S; Olin J
Am J Alzheimers Dis Other Demen; 2010 Dec; 25(8):627-33. PubMed ID: 21131668
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
Farlow MR; Cummings JL; Olin JT; Meng X
Am J Alzheimers Dis Other Demen; 2010 Jun; 25(4):347-52. PubMed ID: 20392862
[TBL] [Abstract][Full Text] [Related]
14. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
15. Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms.
Marin DB; Green CR; Schmeidler J; Harvey PD; Lawlor BA; Ryan TM; Aryan M; Davis KL; Mohs RC
J Am Geriatr Soc; 1997 Nov; 45(11):1331-8. PubMed ID: 9361658
[TBL] [Abstract][Full Text] [Related]
16. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
17. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
18. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
19. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
Schmitt FA; van Dyck CH; Wichems CH; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
